Pharmacia parecoxib

Pharmacia will submit additional data to FDA in 12 to 18 months following July 13 "not approvable" letter for its injectable COX-2 inhibitor parecoxib. The letter "indicated that there were deficiencies in the application," and requested confirmatory data, Pharmacia said. The application was filed in September 2000